Compare PEW & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEW | ACRV |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | 50 | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.6M | 68.5M |
| IPO Year | N/A | 2022 |
| Metric | PEW | ACRV |
|---|---|---|
| Price | $2.50 | $1.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.75 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 895.6K | 460.7K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.25 | N/A |
| Revenue Next Year | $7.96 | $568.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.25 | $1.20 |
| 52 Week High | $7.19 | $3.56 |
| Indicator | PEW | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 32.65 |
| Support Level | $2.25 | $1.38 |
| Resistance Level | $3.22 | $2.20 |
| Average True Range (ATR) | 0.13 | 0.12 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 22.91 | 2.68 |
GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition and related accessories. The Company's firearm products are ordered and paid for by customers online through the Company's eCommerce site and mobile app and are delivered to them on-premises through their choice of federal firearm licensed dealers nationwide. The Company's network of localized firearm dealers perform background checks on firearms purchasers and complete sales forms as mandated by federal and state firearm regulations.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.